4 SC Aktie - VSC

Professionelle Tools für Privatanleger.

Premium

Current Price

1,07

Gebot

1,05

Fragen

1,09

Volumen

26.690

1,05 Tagesbereich 1,11

1,05 52-Wochen-Bereich 9,50

Marktkapitalisierung

10,822M

Handelsende

1,10

Handelsbeginn

1,11

Letzte Trade

1.05

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

10.511

Ausgegebene Aktien

10.114.009

Dividendenrendite

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

Erlöse

345k

Nettogewinn

-8,33M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.4sc.com

Hauptsitz

Munich, Deu

Gegründet

4 SC AG is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker VSC. The last closing price for 4 SC was 1,10 €. Over the last year, 4 SC shares have traded in a share price range of 1,05 € to 9,50 €.

4 SC currently has 10.114.009 shares in issue. The market capitalisation of 4 SC is 11,13 € million.

4SC's Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat ...

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune...

4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune...

European Medicines Agency Adopts Positive Opinion for Orphan Medicinal Product Designation for 4SC's Resminostat to Treat Hep...

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune...

FDA Grants Orphan Drug Designation to 4SC's Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma

4SC AG (FWB:VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.095	-8.15450643777	1.165	1.2749999	1.05	12573	1.17401459	DE
4	-1.93	-64.3333333333	3	4.19	1.05	25239	1.64793186	DE
12	-1.74	-61.9217081851	2.81	4.19	1.05	10511	1.76145828	DE
26	-3.5	-76.5864332604	4.57	6.4	1.05	8797	2.50157712	DE
52	-6.9699999	-86.691542123	8.0399999	9.5	1.05	5302	3.19450541	DE
156	-0.75	-41.2087912088	1.82	11.2	1.05	3860	4.17426086	DE
260	-0.645	-37.6093294461	1.715	11.2	1.05	5467	2.80467067	DE

VSC - Frequently Asked Questions (FAQ)

What is the current 4 SC share price?

The current share price of 4 SC is 1,07 €

How many 4 SC shares are in issue?

4 SC has 10.114.009 shares in issue

What is the market cap of 4 SC?

The market capitalisation of 4 SC is EUR 11,13M

What is the 1 year trading range for 4 SC share price?

4 SC has traded in the range of 1,05 € to 9,50 € during the past year

What is the reporting currency for 4 SC?

4 SC reports financial results in EUR

What is the latest annual turnover for 4 SC?

The latest annual turnover of 4 SC is EUR 345k

What is the latest annual profit for 4 SC?

The latest annual profit of 4 SC is EUR -8,33M

What is the registered address of 4 SC?

The registered address for 4 SC is FRAUNHOFERSTR. 22, PLANEGG-MARTINSRIED, MUNICH, 82152

What is the 4 SC website address?

The website address for 4 SC is www.4sc.com

Which industry sector does 4 SC operate in?

4 SC operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
GPI1China Oil Gas Gr	0,0245 € (58,06%)	400
UE22US Energy Corp	1,875 € (52,44%)	145,9k
1SSNextech3d Ai Corp	0,0266 € (38,54%)	127,5k
NB11Vaxart Inc	0,615 € (35,11%)	172,13k
MZBMexco Energy Corp	9,40 € (32,39%)	1,03k
L09Lithium Energi Exploration Inc	0,005 € (-37,50%)	350
TO1Collective Metals Inc	0,031 € (-27,23%)	100,25k
E3O1Nexoptic Technology Corp	0,006 € (-25,00%)	23,29k
WIG1Wige Media AG	0,015 € (-23,08%)	8,52k
36GGBM Resources Limited	0,0035 € (-22,22%)	22,8k
D7GNel ASA	0,2082 € (-4,32%)	3,44M
TUI1Tui AG	6,28 € (-5,56%)	2,33M
PLUNPlug Power Inc	1,124 € (-0,55%)	2,27M
N04NuCana plc	0,102 € (-22,14%)	2,06M
LHADeutsche Lufthansa AG	6,818 € (-3,48%)	1,9M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

4 SC AG (VSC)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über 4 SC AG

VSC Neueste Nachrichten

4SC's Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat ...

4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma

European Medicines Agency Adopts Positive Opinion for Orphan Medicinal Product Designation for 4SC's Resminostat to Treat Hep...

FDA Grants Orphan Drug Designation to 4SC's Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma

4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model

4SC's Vidofludimus Inhibits IL-17 Production by Interference With the JAK/STAT and NF-B Pathways

4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat

4SC Announces Treatment of First Patient in Phase I TOPAS Study with the selective HDAC inhibitor 4SC-202

4SC Announces Financial Results 2010

VSC - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

4 SC AG (VSC) Börsenkurse

4 SC AG (VSC)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über 4 SC AG

VSC Neueste Nachrichten

4SC's Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat ...

4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma

European Medicines Agency Adopts Positive Opinion for Orphan Medicinal Product Designation for 4SC's Resminostat to Treat Hep...

FDA Grants Orphan Drug Designation to 4SC's Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma

4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model

4SC's Vidofludimus Inhibits IL-17 Production by Interference With the JAK/STAT and NF-B Pathways

4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat

4SC Announces Treatment of First Patient in Phase I TOPAS Study with the selective HDAC inhibitor 4SC-202

4SC Announces Financial Results 2010

VSC - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Anmelden

Werbung entfernen